l-687781 has been researched along with Pneumonia--Pneumocystis* in 2 studies
2 other study(ies) available for l-687781 and Pneumonia--Pneumocystis
| Article | Year |
|---|---|
L-687,781, a new member of the papulacandin family of beta-1,3-D-glucan synthesis inhibitors. I. Fermentation, isolation, and biological activity.
A new beta-1,3-D-glucan synthesis inhibitor, L-687,781 is produced by the cultivation of Dictyochaeta simplex ATCC 20960. L-687,781 exhibits potent in vitro antifungal activity as well as anti-Pneumocystis activity in a rat model. Topics: Animals; Antifungal Agents; beta-Glucans; Candida; Candidiasis; Cryptococcus neoformans; Disease Models, Animal; Fermentation; Fungi; Glucans; Male; Mice; Mitosporic Fungi; Pneumonia, Pneumocystis; Pyrans; Rats; Rats, Inbred Strains | 1991 |
Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.
Pneumocystis carinii pneumonia is a major cause of death in AIDS patients in the United States. The presently available treatments have limited use due to a high incidence of adverse reactions. Therefore, there is an urgent need for a safer method for treatment and prevention of this disease. Recent evidence has suggested that P. carinii is related to fungi and that the wall of the cyst form contains 1,3-beta-glucan as a major constituent. Based on this, several proposed 1,3-beta-glucan synthesis inhibitors were evaluated for their ability to control P. carinii pneumonia in vivo. Compounds from two classes of 1,3-beta-glucan synthesis inhibitors, the echinocandins and papulacandins, were found to be effective against P. carinii. Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Candida albicans; Disease Models, Animal; Echinocandins; Glucans; Lung; Male; Peptides; Peptides, Cyclic; Pneumocystis; Pneumonia, Pneumocystis; Pyrans; Rats; Rats, Inbred Strains; Sulfamethoxazole; Trimethoprim | 1990 |